Using Therapeutic Peptides to Treat Permanent Hypoparathyroidism with Mark Sumeray MD Amolyt Pharma TRANSCRIPT
Download PDFDec 27, 2022
Dr. Mark Sumeray is the Chief Medical Officer of Amolyt Pharma, focusing on rare diseases that affect the endocrine system, the hormonal system that regulates essential body functions. Despite the surgeon's best efforts, the parathyroid glands may be damaged or removed when operating on the thyroid gland creating permanent hypoparathyroidism. As a result, the body does not produce sufficient levels of the parathyroid hormone, which regulates the level of calcium in the blood. Current treatment includes large doses of calcium tablets and vitamin D, which does not address disabling symptoms and long-term complications for the kidney, heart, and brain.
Mark explains, "If you have a deficiency of a hormone, in this case, the parathyroid hormone, then the most obvious thing to do is to replace the missing hormone by giving the hormone or something very similar to the hormone to the patient. So instead of the glands producing the hormone as they should do in the normal situation, in this case, we give something that acts like parathyroid hormone by injection."
"The company has a peptide, which is a type of chemical that is made up of building blocks of amino acids that looks very similar to parathyroid hormone, the missing hormone, but has some important differences to it. It's been specifically synthesized or created by chemists to mimic the action of the natural hormone, and it is given by injection every day to patients. And then, as I mentioned right at the beginning, it's currently in early-stage clinical trials."
@AmolytPharma #Hypoparathyroidism #RareEndocrine #TherapeuticPeptides #Endocrine #RareDisease #Acromegaly #Endocrinology
